Tests HG005 gene therapy for Stargardt disease in children
Tests HG005 gene therapy in children with Stargardt disease, an inherited eye condition.
Plain-language title generated from the registry record
Registry title: An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Source: NCT07063251, who can take part
Where in China
- Eye ENT Hospital of Fudan UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HuidaGene Therapeutics Co., Ltd.
- Trial code
- NCT07063251
- Record updated
- 27 August 2025
- Original description
Stargardt disease type 1 (STGD1) is a rare genetic eye condition that causes progressive vision loss, often beginning in childhood or adolescence. It is the most common form of inherited macular degeneration and can lead to legal blindness. STGD1 is caused by mutations in the ABCA4 gene, which normally helps clear waste from the photoreceptor cells in the retina. When ABCA4 gene doesn't function properly, toxic substances like A2E accumulate and damage the retinal pigment epithelium (RPE), leading to vision loss.Read full original descriptionShow less
An Investigator-initiated, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HG005 in Pediatric Patients With Stargardt Disease (STGD1) Caused by Biallelic ABCA4 Mutations
Stargardt disease type 1 (STGD1) is a rare genetic eye condition that causes progressive vision loss, often beginning in childhood or adolescence. It is the most common form of inherited macular degeneration and can lead to legal blindness. STGD1 is caused by mutations in the ABCA4 gene, which normally helps clear waste from the photoreceptor cells in the retina. When ABCA4 gene doesn't function properly, toxic substances like A2E accumulate and damage the retinal pigment epithelium (RPE), leading to vision loss.
There are currently no approved treatments for STGD1. HG005 is an investigational gene therapy designed to deliver a healthy copy of the ABCA4 gene to the retina. Because the gene is too large to fit into a single AAV (adeno-associated virus) vector, HG005 used two AAV vectors that work together in retinal cells to produce the full-length, functional ABCA4 protein. The goal of HG005 is to restore normal waste removal, protect retinal cells from further damage, and slow or stop vision loss.
Inclusion: Patient ≥ 6 and ≤17 years at the time of signing informed consent, with clinical diagnosis of Stargardt disease; At least one ABCA4 allele on each chromosome; Both eyes must have well-defined macular atrophic lesions consistent with the diagnosis of Stargardt macular dystrophy; Meet visual acuity criteria based on ETDRS letter chart; Subject must agree to contraception during the study; Acceptable hematology, clinical chemistry, urine laboratory, and protocol required eye examination.
Exclusion: Presence of ocular or periocular infection history in either eye within 2 weeks prior to selection; Previous treatment with any gene therapy or cell therapy (e.g., stem cell transplantation); Additional intraocular surgery in study eye 3 months prior to baseline visit; Participation in an oral therapeutic STGD clinical trial within 3 months (or within 5 half-lives after last dose) prior to Screening; Any concomitant treatment that, in the opinion of the investigator, might interfere with the surgical procedure or healing process of the eye; History of HIV or hepatitis A, B, or C infection; Any other conditions that would not allow the potential subject to complete follow-up examinations during the study and would, in the opinion of the investigator, make the potential subject unsuitable for the study; Presence of active intraocular inflammation or uveitis history in either eye; History or presence of corneal dystrophy in the study eye.